CD19 CAR-T cell (Pregene)

靶向CD19的嵌合抗原受体T细胞（普瑞金生物）

Report date: 2024/07/24 14:19:14

Base Information

Drug NameCD19 CAR-T cell (Pregene)
Drug Alias NameAnti-CD19 chimeric antigen receptor T cell therapy - The Beijing Pregene Science and Technology Company
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesShenzhen Pregene Biopharma Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Inactive CompaniesHenan Provincial Cancer HospitalShenzhen Second People'S HospitalPregene (Shenzhen) Biotechnology Co Ltd +[5] 
Active IndicationsN/A
Inactive IndicationsLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksN/A